Tenderwize
Retour à la recherche

Non-exclusive Drug Discount Agreement for Beclometasone/Formoterol

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Nov 30, 2026 · 94 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschl. nicht exkl. AM-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines OH-Mod. zum Wirkstoff Beclometason/Formoterol (ATC-Code nach WHO: R03AK08), ausgen. der Wirkst.100µg/6µg als Dosieraerosol

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed minimum quantities; actual demand depends on prescription behavior and patient numbers, making revenue un...

The buyer may end the Open-House procedure early if exclusive agreements are signed, typically 8-12 months after public...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Nov 2026
  • Conclusion of non-exclusive drug discount agreements under §130a(8) SGB V for Beclometasone/Formoterol (ATC R03AK08) excluding 100µg/6µg aerosol.
  • Open-House model: any eligible pharmaceutical company can participate and accept the terms.
Afficher le résumé complet

Non-exclusive drug discount agreement (Open-House model) for Beclometasone/Formoterol (ATC R03AK08) excluding the 100µg/6µg aerosol dosage form. The agreement is open to all interested pharmaceutical companies meeting eligibility criteria. No guaranteed minimum volumes, no exclusivity, and the agreement terminates by 30.11.2026. The buyer is AOK PLUS for the regions of Saxony and Thuringia. Estimated value is not disclosed.

Risques

No guaranteed minimum quantities; actual demand depends on prescription behavior and patient numbers, making revenue un...

The buyer may end the Open-House procedure early if exclusive agreements are signed, typically 8-12 months after public...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Participant must be a pharmaceutical enterprise as defined in §4(18) AMG.

Eligibility

  • No exclusion grounds under §§123, 124 GWB; must submit self-declaration.

Administrative

  • Compliance with EU sanctions against Russia (Regulation 833/2014); must submit self-declaration.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Beclometasone/Formoterol

Non-exclusive discount agreement for pharmaceutical products containing Beclometasone/Formoterol (ATC R03AK08), excluding the 100µg/6µg dosage as an aerosol. Open-House model with no guaranteed volumes.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Nov 2025 - Nov 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 30, 2026

Détails de la procédure

Date de publication
17 Sep 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
610285-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30